EHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias

Dates: April 25-26, 2025
Location: Berlin, Germany
Chairs: K Döhner, P Vyas, and MT Voso
Collaborating SWG: EHA Specialized Working Group on Acute Myeloid Leukemia

Registration is now open

OverviewThe EHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias (sAML) will focus…

Message from the EHA Board

After more than a decade of tireless work to further EHA’s mission our Executive Director, Carin Smand, has unfortunately announced that she will be leaving our organization.

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

 

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

Brussels Declaration on the Recognition of Professional QualificationsThe future of the Harmonisation of the Haematology Curriculum in Europe

On the occasion of the meeting, there was unanimous support for the

“Brussels Declaration on the Recognition of Professional Qualifications” that follows:

The mobility of haematology trainees is of the utmost importance.

‘Rare Cancers in all EU policies’: Prof Elizabeth Macintyre expresses strong EHA support for the Rare Cancers Europe agenda

On September 28, EHA President Elizabeth Macintyre addressed an audience that included Members of the European Parliament, and officials of the European Commission and the European Medicines Agency, as well as members of the Rare Cancers Europe (RCE) partnership.

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.

Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.

Implementation of the new EU Regulation for In Vitro Diagnostic Medical Devices: a ticking time bomb for the diagnostic sector.

Urgent actions are needed now to prevent a collapse of diagnostic testing.

Evaluation of a single 1.000 mg iron dose as ferric carboxymaltose (FCM) for fatigue treatment in Iron deficient women – PREFER

Fatigue and iron deficiency are prevalent among women of childbearing age. This randomised, placebo-controlled study evaluated the effect of a single intravenous 1.

My EHA